The World Health Organization (WHO) has further delayed the emergency use authorisation (EUA) for Covaxin, the Covid vaccine developed in India, as the global body has sent more technical queries to its manufacturer Bharat Biotech, according to sources.

This delay is likely to adversely affect the international travel plans of Indians, especially students. Without EUA, Covaxin will not be considered an accepted vaccine by most countries around the world. WHO's queries for Bharat Biotech comes despite the Hyderabad-based drug maker asserting that it has submitted all data required for clearance. The indication of a delay comes merely days after the Union Health Ministry hinted that the global body was likely to give its nod anytime soon. "There is a procedure of submitting the documents for approval.

WHO's emergency use authorisation to Covaxin is expected soon," Dr Bharati Pravin Pawar, Union Minister of State in the Health Ministry, had said last Friday, according to a report. Earlier, Dr VK Paul, Chairperson of the National Expert Group on Vaccine Administration, had also said that WHO's approval for Covaxin was likely to come before the end of this month.

ICMR survey shows 73 percent population in Odisha has antibodies

This big thing came out in the study of ICMR regarding Corona

PM Modi launches 'Ayushman Bharat Digital Mission', every Indian to get health ID